ADCT
ADC Therapeutics S.A.NYSEHealthcare$3.78-0.53%ClosedMarket Cap: $480.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.97
P/S
5.73
EV/EBITDA
-6.05
DCF Value
$-10.48
FCF Yield
-30.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.6%
Operating Margin
-133.2%
Net Margin
-175.3%
ROE
66.2%
ROA
-44.1%
ROIC
-42.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $23.1M | 84.5% | $-4.8M | $-6.4M | $-0.04 | — |
| FY 2025 | $81.4M | 90.6% | $-108.4M | $-142.6M | $-1.12 | — |
| Q3 2025 | $16.4M | 92.7% | $-31.0M | $-41.0M | $-0.30 | — |
| Q2 2025 | $18.8M | 95.6% | $-44.1M | $-56.6M | $-0.50 | — |
| Q1 2025 | $23.0M | 91.1% | $-28.5M | $-38.6M | $-0.36 | — |
| Q4 2024 | $16.9M | 91.9% | $-32.4M | $-30.7M | $-0.29 | — |
| FY 2024 | $70.8M | 91.6% | $-130.7M | $-157.8M | $-1.62 | — |
| Q3 2024 | $18.5M | 95.4% | $-35.6M | $-44.0M | $-0.42 | — |
| Q2 2024 | $17.4M | 93.0% | $-29.0M | $-36.5M | $-0.38 | — |
| Q1 2024 | $18.1M | 86.1% | $-33.6M | $-46.6M | $-0.56 | — |
| Q4 2023 | $16.8M | -645.4% | $-40.0M | $-85.0M | $-1.03 | — |
| FY 2023 | $69.6M | 96.4% | $-166.0M | $-240.1M | $-2.94 | — |